Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating the frequency of Neuronal Ceroid Lipofusinosis Type 2 CLN2 in children aged 2 to 6 years who have nonspecific neurological symptoms such as idiopathic seizures, speech disorders, and motor dysfunctions. This multicenter, non-drug screening study focuses on children without hypoxic ischemic encephalopathy, head trauma, or developmental brain anomalies, aiming to better understand the demographic and clinical features of those with possible CLN2 disease. Children first undergo assessments including recording demographic and medical history, seizure frequency, cognitive and language development evaluations, physical exams assessing muscle strength, gait, and coordination, as well as neurological evaluations using EEG and MRI scans. Those showing specific signs like speech disorder with seizures, movement problems, particular EEG responses, or MRI findings will have blood samples taken to measure Tripeptidyl Peptidase 1 enzyme levels. If enzyme activity is low, genetic testing is performed to investigate CLN2 disease. Participants are involved for up to one year during which various clinical, neurological, and imaging evaluations are done. Blood samples are collected for enzyme and genetic analyses. The main outcome measured is the frequency of CLN2 disease in this group. The study tracks each childs symptoms, neurological findings, and imaging results to better identify and understand CLN2 in children with these symptoms.
Actively Recruiting
Healthy Volunteer
Researchers are studying the effects of Body Awareness Therapy BAT on young adults aged 20 to 30 who experience high stress levels. This randomized controlled trial aims to evaluate how BAT influences functional capacity, balance, sleep quality, and psychological state. BAT is a holistic approach that addresses physical, physiological, psychological, and existential aspects of human movement. Participants in the intervention group will take part in BAT exercises in groups of six, performed in supine, sitting, standing, and walking positions. These exercises will be led by a trained instructor twice a week for eight weeks, with the program progressively increasing in intensity every two weeks. The control group will not receive any training during this period but will be assessed alongside the BAT group. Throughout the study, participants will be assessed at the start and after eight weeks using several tests the 6-minute walk test for functional capacity, the single-leg balance test for static balance, the Y-balance test for dynamic balance, the Depression Anxiety Stress Scale-21 for psychological status, and the Pittsburgh Sleep Quality Index for sleep quality. The study will also use the International Physical Activity Questionnaire-Short Form as a secondary measure. All evaluations will be conducted in person by the research team.
Actively Recruiting
Multiple Sclerosis MS is a long-lasting neurological condition that can affect daily activities, movement, and quality of life. This research evaluates how a high-intensity interval training HIIT program using a stationary bicycle impacts maximum walking distance, fatigue, balance, muscle strength, endurance, gait speed, and quality of life in people with MS. The study includes participants with mild, moderate, and severe disability levels based on the Expanded Disability Status Scale EDSS. Participants will take part in a bicycle-based HIIT program involving five 3-minute high-intensity intervals at 85-90% of their maximum heart rate, interspersed with active rest periods at 50-60% maximum heart rate. Each session lasts 20 minutes, including warm-up and cool-down, and sessions occur three times per week for 8 weeks. The study uses a triple-blind design to reduce bias, with assessments done before starting, immediately after the program, and 4 weeks later. During the study, participants will undergo evaluations of walking distance, fatigue, muscle strength and endurance, gait speed, balance, and quality of life at three time points baseline, post-treatment, and follow-up. The research aims to help tailor personalized HIIT exercise programs for MS patients based on their disability level. The total participation spans about 12 weeks including the follow-up period.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of LY4268989 combined with mirikizumab compared to mirikizumab alone in adults with moderately to severely active ulcerative colitis UC. This Phase 2, randomized, double-blind study focuses on treatment for UC, aiming to determine whether the combination improves clinical remission and response rates. Participants will receive either LY4268989 orally along with mirikizumab administered first intravenously then subcutaneously, or mirikizumab with a placebo oral treatment. Responders during the study will be re-randomized for a second study period. Treatment lasts approximately 104 weeks with up to 21 visits. Throughout the study, participants will attend regular visits for assessments including clinical remission status using the modified Mayo Score at weeks 12, 24, and 48, as well as endoscopic improvement and symptomatic remission. Safety and response to treatment will be monitored over about 118 weeks of total participation.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of LY4268989 compared to a placebo in adults with moderately to severely active ulcerative colitis UC. The study involves participants aged 18 to 80 who have had UC for at least three months and have active symptoms confirmed by specific scoring methods. This Phase 2 clinical trial is sponsored by Eli Lilly and Company and focuses on treatment effects over a long period. Participants will receive oral doses of LY4268989 or a matching placebo in a randomized, double-blind design. The study includes two experimental dose groups of LY4268989 and one placebo group. Treatment and evaluation will continue for up to approximately 108 weeks, excluding the screening period. During the trial, participants will be regularly assessed for clinical remission and response using the Modified Mayo Score at weeks 10 and 52. Researchers will monitor symptomatic responses and drug levels in the blood up to week 52. Safety and effectiveness data will be collected throughout the study, with the overall duration lasting up to about two years.
Actively Recruiting
Researchers are evaluating whether combining mirikizumab with tirzepatide can reduce or eliminate symptoms of moderately to severely active ulcerative colitis UC and help participants lose at least 10% of their body weight. This phase 3b study focuses on adults with UC who are also obese or overweight, comparing treatment with mirikizumab plus tirzepatide against mirikizumab plus placebo. The study is sponsored by Eli Lilly and Company and aims to better understand treatment effects on UC symptoms and weight loss. Participants receive mirikizumab first by intravenous infusion, followed by subcutaneous injections of mirikizumab. They are randomly assigned to also receive either tirzepatide or a placebo via subcutaneous injection. Treatment lasts up to 52 weeks. The study is double-blinded, so neither participants nor researchers know who receives tirzepatide or placebo during the trial. Throughout the study, participants undergo regular monitoring including clinical assessments to evaluate remission and response of UC symptoms, endoscopic exams, and histologic evaluations. Researchers measure the percentage of participants who achieve both clinical remission and significant weight loss at week 52. The total participation time is up to 61 weeks, including screening and treatment. Safety and effectiveness are closely tracked during and after treatment.
Actively Recruiting
This trial investigates the safety and effectiveness of mirikizumab combined with tirzepatide versus mirikizumab with placebo in adults who have moderately to severely active Crohns disease along with obesity or overweight. The study is a phase 3b clinical trial and aims to assess how well these treatments work together to improve disease activity and reduce weight. Participants are randomly assigned to one of two groups one receives mirikizumab intravenously followed by subcutaneous administration along with tirzepatide given subcutaneously the other group receives mirikizumab in the same way but with a placebo injection instead of tirzepatide. Treatments are given according to a defined schedule over the course of the study, which lasts up to 61 weeks. Throughout the trial, participants undergo regular monitoring including clinical assessments for Crohns disease activity, endoscopic evaluations, and measurements of body weight. Researchers track outcomes like clinical remission, endoscopic remission, and weight loss at various time points, especially at Week 52. Safety and tolerability are also carefully observed during the study period that may extend up to 61 weeks.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the clinical effectiveness of total pulpotomy, radicular pulpotomy, and root canal treatment in mandibular premolar and molar teeth diagnosed with symptomatic irreversible pulpitis. The study aims to compare these treatments in terms of postoperative pain control and treatment success over time. A total of 99 teeth will be included and randomly assigned to one of the three treatment groups to assess outcomes using standardized protocols. The study involves three treatment groups total pulpotomy, radicular pulpotomy, and root canal treatment. Total pulpotomy consists of removing the coronal pulp and applying mineral trioxide aggregate MTA after achieving hemostasis. Radicular pulpotomy involves removing pulp tissue a few millimeters below the canal orifices, followed by MTA application. Root canal treatment includes cleaning and shaping of the root canals with irrigation and obturation using a calcium silicate-based sealer. All treated teeth will receive a final restoration with glass ionomer cement and composite resin. Participants will receive local anesthesia and undergo treatment according to their assigned group. Postoperative pain will be recorded using a visual analog scale at specified times up to 7 days after treatment. Clinical and radiographic evaluations to assess treatment success and periapical health will occur at 3, 6, and 12 months. Additional assessments include restorative integrity and pulp sensibility testing. Patients will be monitored for up to one year, with measures of pain and healing recorded as primary outcomes.
Actively Recruiting
This research focuses on patients with sickle cell disease SCD who have previously taken part in a Novartis-sponsored study using crizanlizumab. The study provides continued access to crizanlizumab for those who are benefiting from the treatment as judged by their doctor. It is a multi-center and multi-national phase IV rollover study aimed at offering ongoing treatment options for these patients. Participants will continue receiving crizanlizumab at the same dose and schedule they had in their prior study. There is no screening period since patients transfer directly from the parent studies. After giving consent, treatment should begin as soon as possible, following the last dose schedule from the parent study. The study will remain open for up to 10 years or until the treatment becomes commercially available and reimbursed, or when the patients no longer need crizanlizumab. During the study, participants will have regular visits to monitor safety and treatment effects. A safety follow-up visit is planned 105 days after the last dose for those who stop treatment. However, this follow-up is not required if patients continue treatment commercially or through approved plans. Researchers will track any treatment-related side effects from the first dose until 105 days after the last dose. Overall participation duration varies based on treatment continuation and availability.
Actively Recruiting
Healthy Volunteer
Researchers are investigating the relationship between spinal mobility, axial rigidity, and fear of movement kinesiophobia in people with Parkinsons disease PD, particularly focusing on those with and without temporomandibular disorders TMD. This study aims to understand how PD-related stiffness and reduced spinal movement may affect jaw function and posture, which could inform better neurological rehabilitation methods. This observational study involves a single evaluation session where participants spinal flexibility, rigidity, and fear of movement will be measured. Assessments include using the Fonseca Anamnestic Index for TMD presence, jaw movement measurement, spinal mobility tests such as the modified-modified Schober test, and posture evaluations. Additional scales like the Movement Disorder Societys Unified Parkinsons Disease Rating Scale and the Tampa Scale for Kinesiophobia will be used to assess rigidity, posture, and fear of movement. Participants will attend one face-to-face session where demographic and clinical information will be collected along with all physical and questionnaire assessments. The primary outcome measured is spinal mobility, while secondary outcomes include axial rigidity, kinesiophobia, postural alignment, and jaw movement. All data will remain confidential and used solely for scientific purposes, with participation being voluntary and monitored during the ON medication state.
1-10 of 12
1